Prime Medicine opened lower at $4.04, compared with its previous close of $4.30. In the last trading session, the stock traded between $3.73 and $4.15. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Prime Medicine is now worth
$ 25.28
Resulting in a loss of
$ 74.72 (74.72%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.42 (-9.65%)
Day High
$4.15
Day Low
$3.73
Day Open
$4.04
Prev Close
$4.30
Volume
66,01,083
1W Return
-21.74%
1M Return
7.77%
3M Return
19.35%
6M Return
19.91%
1Y Return
-0.89%
Fundamentals
Market Cap ($ Mn)
705
PE Ratio
-
PB Ratio
16.39
PEG Ratio
-
ROE
-166.61%
ROCE
-70.61%
EPS (TTM)
$-0.23
Investment Returns
1 Week
-21.74%
1 Month
7.77%
3 Months
19.35%
6 Months
19.91%
9 Months
12.61%
Financials
Quarterly
All values in $ Mn
2.2
Dec 24
1.5
Mar 25
1.1
Jun 25
1.2
Sep 25
0.8
Dec 25
1.2
Jun 26
Updates
11Nov
Prime Medicine prices $125M public offering at $3.50 per share
Prime Medicine priced 35,714,286 shares at $3.50 per share. Gross proceeds estimated at $125.0 million before fees. Underwriters hold option for additional 5,357,142 shares. Total potential proceeds could reach $143.75 million.
2 days ago
25Sep
Prime Medicine gets FDA clearance for PM647 gene editing study
FDA cleared the IND application for PM647, enabling clinical studies for Alpha-1 Antitrypsin Deficiency. Prime Medicine shares fell 6.19% to $2.88 following the announcement. PM647 targets the E342K mutation in the SERPINA1 gene, affecting ~100,000 US patients. Initial clinical data from the Phase 1/2 trial is expected in 2027.
1mo ago
9Jul
Prime Medicine wins Beam arbitration, clears path for PM647
An arbitration tribunal ruled that Prime Medicine Inc.'s PM647 therapy falls within its licensed field under a 2019 agreement with Beam Therapeutics Inc., clearing the company of breach claims and financial liability. PM647 targets the E342K mutation for Alpha-1 Antitrypsin Deficiency using Prime Medicine's LNP delivery platform. Prime Medicine plans to submit an IND/CTA in Q3 2026 and anticipates initial clinical data in 2027.
4mo ago
29Jun
HC Wainwright upgrades Prime Medicine to Buy with $8 target
HC Wainwright & Co. upgraded Prime Medicine from Neutral to Buy with a price target of $8, as analyst Arthur He revised the stock's outlook.
4mo ago
18Jun
Prime Medicine clears NZ regulator for Wilson disease trial
Prime Medicine secured Medsafe clearance for its PM577a Clinical Trial Application, the first authorization for its in vivo Prime Editing therapy targeting Wilson Disease. The company will now initiate a global Phase 1/2 study to test the investigational treatment.
